Immune Disease
Conditions
Keywords
Autoimmune Diseases, Plasmacytoid Dendritic Cells, Type I Interferons, Antibodies, Anti-CD303
Brief summary
The pathogenic role of type I interferons (IFNs) in the development of different autoimmune diseases has been extensively described in the literature. Since plasmacytoid dendritic cells (pDCs) are the main source of type I IFNs, there is evidence of the involvement of pDCs in autoimmune diseases. The CD303 surface protein (also called BDCA-2) is specifically expressed by the pDCs. The hypothesis leading to the realization of this study is to observe, in vitro, an inhibition of the secretion of the type I IFNs by pDCs in the peripheral blood in patients with autoimmune disease, thanks to the action of the anti-CD303 antibody Developed by the LFB Group, which could reduce the inflammatory response and improve patients with autoimmune disease
Interventions
BIOLOGICALMonoclonal anti-cd303 antibody
Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
Sponsors
Laboratoire français de Fractionnement et de Biotechnologies
University Hospital, Lille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study data collection procedures * Patient followed in the department of internal medicine of CHU Lille * Patient with one of the following autoimmune disease, defined according to international criteria: systemic lupus erythematosus, systemic sclerosis, Gougerot-Sjögren syndrome and idiopathic thrombocytopenic purpura * Being socially insured
Exclusion criteria
* Overlapping syndrome with another autoimmune disease * Age ≤18 years * Pregnant or nursing women * People in emergencies * Person incapable of consent * Persons deprived of liberty * Persons without social security cover
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| in vitro determination of the level of type I interferons by immunoenzymatic ELISA method. | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| in vitro determination of the level of type I interferons by immunoassay ELISA (by type of MIA) | Baseline |
| in vitro determination of the level of type I interferons by ELISA immunoassay method in patients treated or not with immunosuppressive or immunomodulatory treatment. | Baseline |
Countries
France
Outcome results
None listed